Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Author:
Publisher
Frontiers Media SA
Subject
Immunology,Immunology and Allergy
Reference117 articles.
1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012
2. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J Clin Oncol,2014
3. [First-line therapy in advanced renal cell carcinoma: a randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) – AN 39/16 of the AUO];Rexer;Urologe A,2017
4. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy;Larkins;Oncologist,2017
5. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012
Cited by 176 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Development of Persistent Gastrointestinal Symptoms in Patients With Melanoma Who Have Had an Immune Checkpoint Inhibitor-Related Gastrointestinal Toxicity;Clinical and Translational Gastroenterology;2024-07-12
2. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells;Cancers;2024-07-07
3. Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy;Cancer Immunology Research;2024-06-24
4. Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies;Frontiers in Immunology;2024-06-11
5. Transforming cancer care: Immunotherapy with advanced drug delivery;Journal of Drug Delivery Science and Technology;2024-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3